Compare Vipshop Holdings Ltd - ADR (VIPS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vipshop Holdings Ltd - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Vipshop Holdings Ltd - ADR trades at $12.71 (market cap $6.07B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.1× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.86% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vipshop Holdings Ltd - ADR for 49 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VIPS | VRTX | |
|---|---|---|
Market Cap | $6.07B | $128.16B |
Volume | 3,134,219 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $20.29 | $557.96 |
52-Week Low | $12.09 | $407.37 |
Typical Hold Time | 49 Days | 120 Days |
Enterprise Value | $2.90B | $122.29B |
Dividend Yield | 4.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vipshop Holdings trades at $12.77, showing modest daily gains of 0.16%. The stock presents compelling value with a P/E of 4.12 and P/S of 0.41, significantly below sector averages. Recent earnings showed mixed results with Q2 2026 missing expectations, but the company maintains strong profitability with 9.82% net margins and 24.44% ROE. Technical indicators show a bullish overall signal despite recent price consolidation near key support levels.
The investment case balances deep valuation discounts against growth challenges. Analyst consensus targets $16.17 (26% upside) with 54% buy ratings, though recent earnings misses and consumer spending concerns warrant caution. Strong cash generation and shareholder returns provide downside protection, making VIPS attractive for value investors despite near-term headwinds.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
